
BTOG endorses the NICE Lung Cancer Quality Standard published on 29 March 2012
This NICE quality standard defines clinical best practice and provides specific, concise quality statements, measures and audience descriptors to provide the public, health and social care professionals, commissioners and service providers with definitions of high-quality care.
Please click here for information
Presentations from BTOG events are available to view in the members' area.
BTOG Thoracic Oncology Course 2012 held 12th and 13th March 2012
BTOG 2012 held 25th to 27th January 2012
Mesothelioma Scientific Study Day 2011 - BTOG/Mesothelioma UK held on Friday 30th September 2011
BTOG Thoracic Neuroendocrine Tumours Study Day 2011 held on Friday 9th September 2011
Pictured at BTOG 2012, Prof Ken O'Byrne (BTOG President).
The 10th conference of BTOG held 25th to 27th January 2012 in Dublin represented a milestone in the progress of the organisation with attendee numbers totaling 634 (an increase of almost 100 on the previous year). There were also more delegates presenting more research than ever before and the number of poster abstract submissions for BTOG 2012 increased by 55% on the previous year and this resulted in an unprecedented total of 199 posters. The poster abstracts for BTOG 2012 have been published in a supplement to the journal Lung Cancer (Volume 75, Supplement 1 Jnauary 2012 ISSN 0169-5002). Speakers and chairs came from the UK, Ireland, Europe, Taiwan, the USA and Canada and accreditation was received by the Royal College of Physicians, London, the Royal College of Surgeons of England and the European Society for Medical Oncology.
![]() |
|
![]() |
|
![]() |
|
![]() |
BTOG aims to improve the care of patients with thoracic malignancies through multidisciplinary education and clinical and scientific research. BTOG represents all the disciplines involved in the care of lung cancer and mesothelioma throughout the UK and includes medical and clinical oncologists, respiratory physicians, surgeons, radiotherapists, radiologists, nurses, pharmacists and scientists. BTOG also aims to provide a Continuing Education Format for all professionals involved in the management of lung cancer and mesothelioma and to act as a body that could both help develop and give advice on thoracic oncology guidelines for patient care and to generate ideas for clinical trials and develop these ideas into full protocols. BTOG does not have or plan to have a trials infrastructure with the group being fortunate to have a professional association with existing trials units in the UK.
BTOG Secretariat
Tel: 0116 250 2811 | Fax: 0116 250 2810
Email: dawn.mckinley@uhl-tr.nhs.uk